Novel approaches in the treatment of multiple myeloma

Despite all the new advances, treatment of multiple myeloma remains very challenging. Table 6 summarizes the outcomes of some of the commonly used treatments from different clinical trails. Treatment with conventional chemotherapy alone resulted in median survival from 18 to 30 months. Aggressive tr...

Full description

Saved in:
Bibliographic Details
Published inMedicine and health, Rhode Island Vol. 86; no. 8; p. 231
Main Authors Abedi, Mehrdad, Elfenbein, Gerald J
Format Journal Article
LanguageEnglish
Published United States Rhode Island Medical Society 01.08.2003
Subjects
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Humans
Multiple Myeloma - diagnosis
Multiple Myeloma - etiology
Multiple Myeloma - therapy
Neoplasm Staging
Prognosis
Stem Cell Transplantation
Online AccessGet full text

Cover

More Information
Summary:Despite all the new advances, treatment of multiple myeloma remains very challenging. Table 6 summarizes the outcomes of some of the commonly used treatments from different clinical trails. Treatment with conventional chemotherapy alone resulted in median survival from 18 to 30 months. Aggressive treatments like VBMCP (vincristine, bleomycin, melphalan, cyclophosphamide, predisone) although resulting in higher response rates, resulted in higher treatment-related mortality and did not have any effect on median and 5 year survival. High dose chemotherapy with stem cell support increased the median survival to around 60 months and resulted in durable complete responses in a significant number of the patients. Some of the newer and promising treatments for multiple myeloma are summarized in Table 7.
ISSN:1086-5462
2327-2228